China's campaign against rare diseases

Weijie ZhaoNational 2022 · DOI

TL;DR

China is making significant strides in its campaign against rare diseases, establishing national expert committees, diagnostic lists, and research funding. Despite progress, challenges remain in diagnosis accuracy, treatment availability, and affordability, highlighting the need for continued scientific, economic, and societal advancements.

What Problem Does This Paper Address?

This paper addresses the significant challenges faced by rare disease patients in China, a population estimated to be between 20-54 million. Unlike in the US and Europe, China lacks a commonly accepted definition for rare diseases and has historically lagged in research and development (R&D) for orphan drugs. The paper highlights the difficulties in diagnosis due to the sheer number of rare diseases, the diversity of their phenotypes, and a general lack of familiarity among medical professionals. Furthermore, it tackles the critical issue of treatment accessibility and affordability, noting that for approximately 95% of rare diseases, no effective therapies exist, and even when available, drugs are often prohibitively expensive.

Methods

The paper doesn't describe a specific experimental method but rather synthesizes information from the 2021 China Conference on Rare Diseases. It draws upon expert opinions, policy discussions, and existing research to provide an overview of the current landscape. Key "methods" discussed in the context of rare disease management include:

  • Second-generation sequencing technologies: Whole-exome sequencing, mitochondrial DNA sequencing, and proteomic analysis are revolutionizing diagnosis by enabling more precise identification of genetic origins.
  • Multidisciplinary Team (MDT) diagnosis: This approach involves physicians from various specialties collaborating to analyze complex symptoms and design patient-centered treatment plans.
  • National rare-disease networks and databases: The establishment of a three-level prevention and control network with 324 hospitals and shared databases (National Rare Disease Direct Reporting System and National Rare Diseases Registry System) aims to improve information sharing and treatment accessibility.
  • Orphan Drug Act (ODA) principles: While China hasn't passed a specific ODA, the paper discusses how policies and strategies are being implemented to encourage R&D and improve access to rare disease treatments, drawing parallels to international ODA frameworks.

Datasets

The paper mentions the following datasets:

  • National Rare Disease Direct Reporting System: Collected 540,000 cases from 291 institutions.
  • National Rare Diseases Registry System: Included over 68,000 cases of 171 rare diseases.
  • Online Mendelian Inheritance in Man (OMIM) database: Mentioned as a resource for identifying pathogenic gene variations.
  • FDA database: Referenced for orphan drug approvals in the US.
  • China's Drug Clinical Trial Registration and Information Publicity Platform: Used to track clinical trials in China.

Key Insights and Ideas

  • The diagnostic odyssey is a major hurdle: Even with advanced sequencing technologies, accurately identifying rare diseases remains challenging due to incomplete knowledge of gene variations and the need for careful interpretation of results in conjunction with clinical phenotypes.
  • Education is paramount: A significant percentage of medical workers in China report never having diagnosed or treated rare diseases, underscoring the urgent need for comprehensive education for medical students and practitioners.
  • MDTs are crucial for complex cases: The highly specialized nature of modern medicine necessitates collaborative diagnostic approaches to effectively manage the diverse and often confusing symptoms of rare diseases.
  • Government policy is a key driver: While commercial incentives for orphan drug R&D are low, government initiatives like national expert committees, diagnostic lists, and research funding are essential for progress.
  • Patient advocacy is growing: The establishment of patient organizations, often led by patients and their families, plays a vital role in providing resources, emotional support, and advocating for policy changes.
  • Affordability remains a critical barrier: Even when treatments are available, their extremely high cost poses a significant challenge for many rare disease families in China.

Key Results

  • China has established a National Expert Committee on Diagnosis, Treatment and Insurance of Rare Diseases (since 2015).
  • Two batches of rare diseases have been listed (121 in the first batch, with a second coming soon).
  • The National Natural Science Foundation of China invested 57.2 million yuan (~9 million US dollars) into rare disease basic research between 2016-2018.
  • A three-level prevention and control network comprising 324 hospitals nationwide has been established.
  • Two national shared databases have collected a substantial number of rare disease cases.
  • MDT workshops at Peking Union Medical College Hospital (PUMCH) have benefited over 127 patients since 2019.
  • A national hospital network facilitates online MDT workshops, aiming to expedite diagnoses.
  • Among the 121 diseases in China's rare disease list, only 74 have available drugs, and 16 of those are not available in China.

Limitations and Future Work

Limitations:

  • Lack of a universally accepted definition: This hinders consistent data collection and policy implementation.
  • Limited R&D capacity: China's pharmaceutical companies lag behind Western counterparts in orphan drug R&D.
  • Diagnostic challenges: Incomplete knowledge of gene variations and the difficulty in distinguishing true pathogenic variants from false positives persist.
  • Treatment accessibility and affordability: For most rare diseases, no drugs are available, and for those that are, the cost is often prohibitive.
  • Geographic disparities: Access to advanced diagnostic and treatment centers is concentrated in major cities, leaving patients in rural areas underserved.

Future Work:

  • Continued scientific and technological advancements in diagnosis and treatment.
  • Further development of economic and societal support systems for rare disease patients.
  • Strengthening government policies and social support mechanisms to address the financial burden of rare diseases.
  • Expanding the rare-disease network and improving access to MDT services nationwide.
  • Encouraging further investment and innovation in orphan drug R&D.

Summary updated

BibTeX
@inproceedings{zhao2022china,
  author = {Weijie Zhao},
  title = {{China's campaign against rare diseases}},
  booktitle = {National},
  year = {2022},
  doi = {10.1093/nsr/nwac015},
}
Figure